| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_1c8cbbf2290b3f3a9988da29598baa2c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_4efa0a5945f45fea2d2bddb778a8cf40 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-55505
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-545
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-541
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-522
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-523
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y02A50-30 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-04 |
| classificationIPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P37-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-08 |
| filingDate |
2010-11-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2018-08-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2bc83f198bcd3f970f0e84cafe5b4899 |
| publicationDate |
2018-08-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-10046040-B2 |
| titleOfInvention |
Multivalent live vector vaccine against Clostridium difficile-associated disease |
| abstract |
The invention relates to a multivalent Clostridium difficile vaccine comprising a Salmonella Typhi live vector comprising the cell binding domain of TcdA toxin (CBD/A) of Clostridium difficile or an antigenic fragment thereof and the cell binding domain of TcdB toxin (CBD/B) of Clostridium difficile or an antigenic fragment thereof and optionally the cell-binding subunit component (CdtB) of binary toxin of Clostridium difficile or an antigenic fragment thereof. The invention further provides methods of inducing an immune response and methods of preventing recurrence of C. difficile infections in subjects. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10982198-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10787652-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10774117-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11001820-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2019112584-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11208633-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11624060-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2017204390-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11535652-B2 |
| priorityDate |
2009-11-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |